TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00683059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: total dose (mg) = body surface area in m2 x study dose (mg/m2) to be injected into a vein once every 3 weeks over 18 months.
Study: NCT05155943

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KALPA X™
Description: Before and after a transseptal puncture, the right atrium (RA), left atrial appendage (LAA), and left upper superior pulmonary vein (LUSPV) will be mapped using the KALPA™ system (WS Software ver. 1.0.229-0 Source control ID: 65f1dbf7) in combination with a commercially available catheter. Subjects will then undergo LAAC as per routine clinical care. The entire LAAC procedure will be conducted as customary practice using standard and approved off-the-shelf equipment (body surface electrodes, catheters, etc.) the operator will be blinded to the KALPA™ and KALPA X™ system information.
Study: NCT04912310

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Argon laser peripheral iridoplasty
Description: Argon laser peripheral iridoplasty was performed in patients with severe acute angle closure glaucoma whose intraocular pressure could not be controlled by medication
Study: NCT00778245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefprozil 500mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefprozil 500mg tablets
Study: NCT02820597

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClariFix device
Study: NCT03118167

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tea polyphenols
Description: Tea polyphenols 0.05g, 0.1g, 0.2g (starches filled up to 0.35g), edible capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AOB-w
Description: Water-soluble antioxidant of bamboo leaves 0.35g, edible capsule

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Edible starches 0.35g, edible capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acrylamide (Potato Chips)
Description: Potato Chips bought from market, corresponding to acrylamide (12.6μg/kg b.w. )

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acrylamide (Potato Chips)
Description: Potato Chips bought from market, corresponding to acrylamide (12.6μg/kg b.w. )

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acrylamide (Potato Chips)
Description: Potato Chips bought from market, corresponding to acrylamide (12.6μg/kg b.w. )
Study: NCT01863628

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: psychoeducation
Study: NCT01636908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 50 mg once daily, oral use, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400 mg, twice daily, oral use, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg once daily, oral use, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10 mg once daily, oral use, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 1250 mg once daily, oral use, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: 100 mg once daily, oral use, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: 800 mg once daily, oral use, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: 960 mg twice daily, oral use, 15-21 days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin biopsy (optional)
Study: NCT01229774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Description: Arcoxia 90 mg once a day in the evening day -1 and 0 and once a day in the morning days 1-7 plus on tablett of placebo every evening

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Voltaren Resinat 75mg once a day on day -1 and 0 in the evening; twice a day (in the morning and in the evening) days 1-7
Study: NCT02295176

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Armolipid Plus

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01508637

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diesel Exhaust
Description: Freshly generated diesel exhaust, diluted to 300 micrograms/cubic meter. Exposures are two hours in duration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diesel Exhaust
Description: Freshly generated diesel exhaust, diluted to 300 micrograms/cubic meter. Exposures are two hours in duration.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Filtered Air
Description: Sham exposure, identical to conditions of diesel exhaust exposure, but with only air filtered of particles and volatile organic compound gases

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Filtered Air
Description: Sham exposure, identical to conditions of diesel exhaust exposure, but with only air filtered of particles and volatile organic compound gases

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terazosin
Description: 2 mg by mouth, 90 minutes prior to exposure initiation

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Terazosin
Description: 2 mg by mouth, 90 minutes prior to exposure initiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: capsule, identical in appearance to terazosin capsule, by mouth, 30 minutes prior to exposure initiation

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: placebo
Description: capsule, identical in appearance to terazosin capsule, by mouth, 30 minutes prior to exposure initiation
Study: NCT01629212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiropramide HCl 100mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octylonium bromide 20mg
Study: NCT01468077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: 8 mg/kg infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: 8 mg/kg infusion
Study: NCT02701998

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth-Enhance Physical Activity Intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Intervention
Study: NCT02825186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loteprendol etabonate 0.5%
Description: Steroid eye drops used after strabismus surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.1%
Study: NCT04398368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given intravesically
Study: NCT01012245

Intervention type: OTHER
Intervention: no intervention
Study: NCT03008109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR-TK Inhibitor
Study: NCT03437135

Intervention type: DIAGNOSTIC_TEST
Intervention: Glasgow Hearing Status Inventory questionnaire
Description: This is a questionnaire of the hearing quality presenting eleven questions. This is allows to determine the quality of the hearing status of the patients. It is enough to answer the various questions yes or no.

Intervention type: DIAGNOSTIC_TEST
Intervention: Glasgow Hearing Status Inventory questionnaire
Description: This is a questionnaire of the hearing quality presenting eleven questions. This is allows to determine the quality of the hearing status of the patients. It is enough to answer the various questions yes or no.

Intervention type: DIAGNOSTIC_TEST
Intervention: Glasgow Hearing Status Inventory questionnaire
Description: This is a questionnaire of the hearing quality presenting eleven questions. This is allows to determine the quality of the hearing status of the patients. It is enough to answer the various questions yes or no.
Study: NCT02432963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified Vaccinia Virus Ankara Vaccine Expressing p53
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT01951404

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for allopurinol)
Study: NCT03372590

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NICU-based rehabilitation bundle
Description: Maternal-driven gestational age-appropriate intervention/activity bundle, including the evidence-based elements of vocal soothing, comforting touch, scent exchange, kangaroo care, and infant massage

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Standard NICU care
Study: NCT04721782

Intervention type: OTHER
Intervention: smoking
Description: to assess the effect of smoking of fetal liver circulation with prenatal Doppler Ultrasonography
Study: NCT01175759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Skin test panel
Description: Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~1. Progesterone 1mmol/L~2. Estradiol 1mmol/L~3. Estrone 3mmol/L~4. Estriol 3mmol/l~   Controls:~5. Saline (NaCl) 0.9%~6. Ethyl Oleate with 10% Benzyl Alcohol~7. Histamine phosphate 1mg/ml (epicutaneous- prick test)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Skin test panel
Description: Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~1. Progesterone 1mmol/L~2. Estradiol 1mmol/L~3. Estrone 3mmol/L~4. Estriol 3mmol/l~   Controls:~5. Saline (NaCl) 0.9%~6. Ethyl Oleate with 10% Benzyl Alcohol~7. Histamine phosphate 1mg/ml (epicutaneous- prick test)
Study: NCT04885348

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group (Dental Home Visits + Dental Home Education Leaflets)
Description: No drugs were given in the Intervention. The intervention group received Dental Home Visits consisted of 6 monthly home visits by oral health therapists/dental home visitors where they deliver dental care advice to the parents for durations of approximately 30 minutes until follow-up at two years. Dental Home Education Leaflets (DHELs) and oral health messages were delivered through a personalized approach that avoids direct persuasion. These messages included information on daily tooth brushing with fluoride toothpaste, controlling dietary sugar intake, and the need for regular dental check-ups. The families were also be provided with information about local dental services available in their vicinity and how to access these services.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group (Dental Home Education Leaflets)
Description: Only Dental Home Education Leaflets were provided every six months for 2 years.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Group (Dental Home Education Leaflets)
Description: Only Dental Home Education Leaflets were provided every six months for 2 years.
Study: NCT01955577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 cholecalciferol
Study: NCT00816322

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acids
Description: EPA 2.1 g/d+DHA 1.1 g/d
Study: NCT02380183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Civco Needle Guidance Device
Description: Needle guidance device will be used while nerve block is performed.
Study: NCT02638688

Intervention type: OTHER
Intervention: ultrasound

Intervention type: OTHER
Intervention: ultrasound

Intervention type: OTHER
Intervention: ultrasound
Study: NCT03362541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MS INFoRm
Description: MS INFoRm incorporates principles of self-management and adult learning theory. The contents address the sources of fatigue, ways of monitoring fatigue, and strategies to reduce fatigue.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Control Group
Description: The usual care webpage will contain content from widely available resources about MS fatigue.
Study: NCT03147196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00816322

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: high oleic oil
Study: NCT02094313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: The aim of this pilot study is to evaluate the efficacy and the safety of a decrease of cholesterol blood levels, induced by taking atorvastatin, on sperm quality of normocholesterolaemic and healthy men without confounding factors.
Study: NCT03147196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene Hydrochloride
Description: Given PO
Study: NCT02297009

Intervention type: PROCEDURE
Intervention: Buccal swab
Description: Buccal swabs will be taken from the volunteers
Study: NCT02623959

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Symptom and quality of life questionnaires completed at baseline and at 10 - 14 days after receiving Saline or Doxycycline.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Symptom and quality of life questionnaires completed at baseline and at 10 - 14 days after receiving Saline or Doxycycline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Patch
Description: Participant given a Fentanyl patch, 12 mcg/hour, which should be worn at follow up visit 5 days after IPC placement.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Patch
Description: Participant given a Fentanyl patch, 12 mcg/hour, which should be worn at follow up visit 5 days after IPC placement.
Study: NCT01124370

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remedē (TM) system
Description: Implantation of the remedē (TM) system, including implantable pulse generator, stimulation lead, and (optional) sensing lead. Nightly provision of unilateral transvenous phrenic nerve therapy during sleep periods.
Study: NCT04063605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Pilates
Description: This exercise model focus on the awareness of the neutral position of the spine and strengthen the deep postural muscles of the spine. Training of trunk muscles is emphasized and trunk stabilization is achieved and more difficult activities are initiated and thus, body awareness is improved. There are general principles to be followed during exercises. These; The principle of concentration is respiration, central focus, control, stability and isolation. These principles are achieved by simultaneous muscle activation of muscles responsible for trunk stabilization (multifidus, diaphragm, transversus abdominis and pelvic floor muscles). In order for an exercise to become a clinical pilates exercise, trunk stabilization must be ensured and breath control should be established in each exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classic Physiotherapy
Description: This exercise program will include strengthening, stretching, posture exercises, balance and gait exercises. Aim is to improve muscle strength and prevent shortness of muscles. Also, balance and gait exercise aim to improve walking capacity.
Study: NCT00807105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: H-coil dTMS
Description: treatment with deep TMS stimulation.
Study: NCT02926924

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wound Vac
Description: a therapeutic technique using a vacuum dressing to promote healing in acute or chronic wounds and enhance healing of first and second degree burns.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dressing
Description: standard dressing with drain tube and bandage
Study: NCT04742062

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ApTOLL
Description: ApTOLL is a Toll-like receptor 4 (TLR4) antagonist, a receptor that is involved in innate immune responses but also responds to tissue damage, and therefore it is directly involved in a large number of diseases where the inflammatoryy response is involved. ApTOLL has demonstrated specific binding to human TLR4 as well as a TLR4 antagonistic effect, reducing inflammation and improving outcome after different disease models.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ApTOLL
Description: ApTOLL is a Toll-like receptor 4 (TLR4) antagonist, a receptor that is involved in innate immune responses but also responds to tissue damage, and therefore it is directly involved in a large number of diseases where the inflammatoryy response is involved. ApTOLL has demonstrated specific binding to human TLR4 as well as a TLR4 antagonistic effect, reducing inflammation and improving outcome after different disease models.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mL 0.9% Sodium Chloride solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mL 0.9% Sodium Chloride solution
Study: NCT00848510

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EMD 525797
Description: Abituzumab will be administered as an intravenous infusion for an hour at a dose of 250 milligram (mg) to 1500 mg at Weeks 1, 3 and 5. In case of clinical benefit (stable disease \[SD\], complete response \[CR\], or partial response \[PR\]) that will be assessed by the Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0) during initial 6 Weeks, subjects will be allowed to continue treatment at the start of Week 7 at the given dose (250 mg or 500 mg or 1000 mg or 1500 mg) every second week until intolerance to treatment, withdrawal of consent, or the subject is no longer benefiting from treatment in the opinion of the Investigator.
Study: NCT01399762

Intervention type: DEVICE
Intervention: mechanical recanalization
Description: Endovascular thrombus extraction by mechanical recanalization devices
Study: NCT03378037

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: 20 minutes of acupuncture treatment, twice a week for 2 weeks. Acupoints will be manually stimulated every 10 minutes.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: 20 minutes of acupuncture treatment, twice a week for 2 weeks. Acupoints will be manually stimulated every 10 minutes.
Study: NCT02034019

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Punctum Plug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Punctum Plug
Study: NCT04632043

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation
Description: Endotracheal intubation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation
Description: Endotracheal intubation
Study: NCT01275768

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Endoscopic radio-frequency ablation
Description: Endobiliary radiofrequency catheter is 8Fr in diameter and can easily be passed over a 0.035 guide wire through the biopsy channel of a duodenoscope at the time of endoscopic retrograde cholangiography (ERC). Its use in the biliary system was heralded by animal experiments following which power settings of 7-10 Watts for 2 minutes were found to provide adequate ablation. The ablation results in charring of the tumor and this is expected to enhance the patency of SEMS

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic radio-frequency ablation
Description: Endobiliary radiofrequency catheter is 8Fr in diameter and can easily be passed over a 0.035 guide wire through the biopsy channel of a duodenoscope at the time of endoscopic retrograde cholangiography (ERC). Its use in the biliary system was heralded by animal experiments following which power settings of 7-10 Watts for 2 minutes were found to provide adequate ablation. The ablation results in charring of the tumor and this is expected to enhance the patency of SEMS
Study: NCT05267795

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimentally-induced pain
Description: Specific pain levels were applied on the participants' fingernails in each of 40 experimental trials using pressure algometry.
Study: NCT01270828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Tablets, 82.5 to 660mg, once per day. Duration: 19 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo, 82.5 to 660mg, once per day. Duration: 13 weeks
Study: NCT02429908

Intervention type: DEVICE
Group type: OTHER
Intervention: TM-Ardis Interbody
Description: The TM Ardis implant is a single device manufactured wholly from Trabecular Metal™ (porous tantalum) material, a highly porous, three-dimensional biomaterial designed for biologic fixation. is indicated for use with autogenous bone graft as an intervertebral body fusion device at one or two contiguous levels in the lumbosacral region (L2- S1) in the treatment of degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis or retrolisthesis at the involved level(s).
Study: NCT04292470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Description: Amitriptyline tablet